EA
TMDX icon

Emerald Advisers’s Transmedics TMDX Stock Holding History

Emerald Advisers’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.6M Buy
490,491
+147,700
+43% +$12.5M 0.77% 60
2026
Q1 		$34.1M Sell
342,791
-8,558
-2% -$1.12M 1.08% 28
2025
Q4 		$42.7M Sell
351,349
-36,239
-9% -$4.55M 1.32% 16
2025
Q3 		$43.5M Sell
387,588
-51,741
-12% -$6.06M 1.39% 17
2025
Q2 		$58.9M Sell
439,329
-15,465
-3% -$1.7M 2.16% 4
2025
Q1 		$30.6M Buy
454,794
+83,083
+22% +$5.71M 1.38% 21
2024
Q4 		$23.2M Buy
371,711
+220,804
+146% +$20.6M 0.9% 44
2024
Q3 		$23.7M Sell
150,907
-172,443
-53% -$26.6M 0.92% 45
2024
Q2 		$48.7M Sell
323,350
-200,070
-38% -$24M 2.04% 4
2024
Q1 		$38.7M Buy
523,420
+7,067
+1% +$582K 1.56% 10
2023
Q4 		$40.8M Buy
516,353
+73,807
+17% +$4.45M 1.74% 9
2023
Q3 		$24.2M Buy
442,546
+6,453
+1% +$465K 1.17% 21
2023
Q2 		$36.6M Buy
436,093
+5,541
+1% +$424K 1.6% 7
2023
Q1 		$32.6M Sell
430,552
-132,115
-23% -$9.14M 1.56% 8
2022
Q4 		$34.7M Buy
562,667
+67,741
+14% +$3.6M 1.68% 7
2022
Q3 		$20.7M Buy
494,926
+97,361
+24% +$4.23M 1.07% 33
2022
Q2 		$12.5M Buy
397,565
+116,612
+42% +$3.11M 0.64% 65
2022
Q1 		$7.57M Buy
280,953
+36,137
+15% +$647K 0.29% 103
2021
Q4 		$4.69M Sell
244,816
-8,562
-3% -$215K 0.17% 114
2021
Q3 		$8.38M Sell
253,378
-47,086
-16% -$1.44M 0.3% 105
2021
Q2 		$9.97M Sell
300,464
-304,511
-50% -$8.44M 0.36% 100
2021
Q1 		$25.1M Sell
604,975
-67,905
-10% -$2.09M 0.91% 42
2020
Q4 		$13.4M Buy
672,880
+21,697
+3% +$321K 0.44% 92
2020
Q3 		$8.97M Sell
651,183
-18,284
-3% -$313K 0.37% 92
2020
Q2 		$12M Buy
669,467
+216,389
+48% +$3.38M 0.52% 73
2020
Q1 		$5.47M Buy
453,078
+1,536
+0.3% +$25.7K 0.32% 95
2019
Q4 		$8.58M Buy
451,542
+243,034
+117% +$4.46M 0.36% 101
2019
Q3 		$4.95M Sell
208,508
-3,000
-1% -$71.9K 0.23% 107
2019
Q2 		$6.13M Buy
+211,508
New +$5.77M 0.25% 108

Other funds holding TMDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Emerald Advisers's TMDX Position: Q2 2026 in Review

Emerald Advisers increased its Transmedics (TMDX) stake by 43% in Q2 2026, buying an estimated $12.5M and bringing the position to 490,491 shares worth $32.6M. The position accounts for 0.77% of the portfolio, ranked #60.

Emerald Advisers first reported a position in TMDX in Q2 2019 and has held it in 29 quarters since. The position peaked at $58.9M in Q2 2025. 374 funds tracked by Wall St. Rank hold TMDX as of Q2 2026.

  • Emerald Advisers held 490,491 shares of Transmedics worth $32.6M as of Q2 2026.
  • Emerald Advisers bought 147,700 Transmedics shares in Q2 2026, an estimated $12.5M.
  • Transmedics made up 0.77% of Emerald Advisers's portfolio in Q2 2026, its #60 holding.
  • Emerald Advisers first reported a position in Transmedics in Q2 2019 and has held it in 29 quarters since.
  • Emerald Advisers's Transmedics position peaked at $58.9M in Q2 2025.
  • 374 funds tracked by Wall St. Rank held Transmedics as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.